The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
about
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapyFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to ChemoradiotherapyProgress in personalizing chemotherapy for bladder cancerCo-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancerEnhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Nucleoside analogs: ready to enter the era of precision medicine?Harnessing Solute Carrier Transporters for Precision Oncology.ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy.Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer.Recent advances in medical therapy for metastatic urothelial cancer.Age-related decrease of adenosine-mediated relaxation in rat detrusor is a result of A2B receptor downregulation.
P2860
Q26862139-CB5C3B5D-8D5D-4CC1-A6E7-FDBA209A1546Q34278209-BB9E839B-C3FC-42B4-A653-5EB50E17256DQ34646772-70A6D629-D234-4EC7-B933-460E50E71EAEQ35066350-B8D5DD00-DECD-4AAE-A47D-4C0140DE2A47Q35495280-D30E6D7D-7423-4632-B052-348D7F93DB50Q35779460-E08BC0E4-25D4-4E23-BD94-CE55BDE8AFF2Q36099310-5761D6A2-7E82-4FBF-BB6B-D8FC44557209Q36342657-B5588ECC-70B4-4714-A75A-CD461A6AE1C3Q38842938-14243ABA-5F48-42D7-BFCA-DE8F10939946Q39204754-9CF395C5-AC8B-4CA4-98BB-0D7689B9791FQ41923384-91518120-BF72-4C3C-B341-0CA9C7B44A33Q50569337-05B8D736-4F0E-441F-8DDF-A306A7338D86Q51206876-F5350ED0-CF4B-4D57-8BC8-1BAB33AF8281Q51728141-5E2208AD-4176-4884-9E16-895A21B376CEQ52647343-6ADB8297-297F-48C3-8745-FC757BD59386Q54172413-76D1F98F-0E10-471F-AB16-4C8276595541
P2860
The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The prognostic significance of ...... ased combination chemotherapy.
@en
The prognostic significance of ...... ased combination chemotherapy.
@nl
type
label
The prognostic significance of ...... ased combination chemotherapy.
@en
The prognostic significance of ...... ased combination chemotherapy.
@nl
prefLabel
The prognostic significance of ...... ased combination chemotherapy.
@en
The prognostic significance of ...... ased combination chemotherapy.
@nl
P2093
P2860
P1433
P1476
The prognostic significance of ...... ased combination chemotherapy.
@en
P2093
Hironao Yasuoka
Nagahide Matsumura
Takeshi Inagaki
Yasuo Kohjimoto
Yasuo Ohashi
Yasushi Nakamura
Yoshihito Nanpo
P2860
P304
P356
10.1111/J.1464-410X.2010.09932.X
P433
P577
2010-12-16T00:00:00Z